MannKind (MNKD)
(Delayed Data from NSDQ)
$5.70 USD
+0.09 (1.60%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.72 +0.02 (0.35%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNKD 5.70 +0.09(1.60%)
Will MNKD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MNKD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNKD
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MNKD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Other News for MNKD
Buy Recommendation: MannKind’s Afrezza Shows Promising Efficacy and Market Growth Potential
MannKind announces 17-week results from INHALE-3 study
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
MannKind initiated with bullish view at Rodman & Renshaw
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions